News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

New Report Reveals the Potential Reach of Direct Primary Care to Employers

Nice Healthcare

A new report published by an independent risk management consulting firm, Milliman, commissioned by Nice Healthcare, shows that the Nice Healthcare’s integrated healthcare model addresses services that are used by 89% of healthcare utilizers in a typical large employer commercial health benefit plan, based on a study of historical data. The data underlying the research included 58 million member months of exposure and more than $28 billion in allowed claims. “Our focus is on how we can bring better access at an affordable price to small businesses,” says Thompson Aderinkomi, CEO of Nice Healthcare. “Our model also provides support to health plans by being the first line of care enabling providers to only see the patients who need them most.” Using a mix of technology, logistics, and expert clinical care, Nice Healthcare brings a fully integrated clinic to the patient, providing in-home and virtual primary care, mental health therapy, physical therapy, and medications. The service is a direct-to-employer benefit and can help health plans avoid high-dollar claims and wasteful care. Aligned with Nice’s mission of accessible services, the study found that the services Nice can address make up the majority of healthcare costs typically incurred at urgent care facilities or via telehealth. With Nice, you can get a visit, labs, x-rays and more right in your home. Nice also offers virtual visits, giving patients quick answers to their healthcare questions without relying on insurance, networks, or scheduling around busy work days. To read the full study visit https://www.milliman.com/en/insight/Benchmarking-cost-and-utilization-of-direct-primary-care-services. Nice Healthcare is making truly integrated comprehensive healthcare accessible, allowing patients to easily get care for their everyday needs. Using a mix of technology, logistics, and expert clinical care, they bring a fully integrated clinic to you, providing in-home and virtual primary care, mental health therapy, and physical therapy. Their clinicians can also offer patients x-rays, 35 labs and blood draws and a formulary with over 550 medications with no out-of-pocket costs. Since launching in Minnesota in 2017, Nice has expanded its integrated care services to 12 states. Contact Details Nice Healthcare pr@nice.healthcare +1 586-461-2103 pr@nice.healthcare Company Website https://www.nice.healthcare/

November 10, 2022 09:00 AM Eastern Standard Time

Article thumbnail News Release

The NIH Has Given BioRestorative Therapies A Stamp Of Approval

BioRestorative Therapies, Inc.

BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes. BioRestorative’s novel drug BRTX-100, which is approved by the Food and Drug Administration (FDA) to enter Phase 2 clinical trials, targets damaged and degenerating discs. The Company is well into its trial, a 99-patient prospective, randomized, double-blinded, controlled study, the gold standard of its kind. BRTX-100 is an autologous stem cell product that uses the patient’s own stem cells, which are harvested, cultured, combined with their own autologous platelet lysate and then injected directly into the affected disc to initiate the healing and repair process. Previous human investigator-initiated studies using a similar product to BRTX-100 (but arguably less potent) have shown a reduction in pain and increase in function in excess of the stated primary endpoints in BioRestorative’s phase 2 protocol. This fascinating opportunity presents a study that is highly suggestive of the potential outcomes for which they are currently processing. In addition, the treatment is anticipated to be safer, cheaper and more effective with a single treatment. BioRestorative’s other product — ThermoStem — has highly promising results in the treatment of obesity and related diseases. Obesity affects over 40% of Americans, and BioRestorative is developing a novel stem-cell population — brown adipose tissue — that shows signs of regulating metabolic activity and reducing excess fat. BioRestorative Therapies Has Joined The Leagues Of 23andMe, Qualcomm and Naviscan In September 2021, BioRestorative was awarded a Small Business Technology Transfer (STTR) phase I grant for $256,000. The project seeks to evaluate the therapeutic effects on the company’s hypoxic cultured bone marrow derived mesenchymal stem cells (BRTX-100) after encapsulation with a PEG-peptide hydrogel. The work is being done in collaboration with Dr. Lori Setton, Chair of the Department of Biomedical Engineering at Washington University in St. Louis. SBIR is a federal program coordinated by the Small Business Administration that funds research and development. STTR is a Small Business Innovation Research (SBIR) sister program. The programs are one of the largest sources of funding for early-stage companies. Big-name companies like 23andMe Holding Co. (NASDAQ: ME), Qualcomm Inc. (NASDAQ: QCOM) and Naviscan Inc. were awarded SBIR and STTR funding, which helped them become the companies they are today. SBIR and STTR programs are highly competitive programs that foster and encourage small businesses to engage in Federal Research/Research and Development (R/R&D) with the potential for product commercialization. Through this highly competitive awards-based program, SBIR and STTR enable small businesses to explore their technological potential and provide the incentive to profit from its commercialization. SBIR and STTR are like gold mines for smaller companies. Borrowing from a bank is often difficult for new, innovative businesses because they lack collateral and revenue to help secure loans. While venture capital often fills the gap, it’s not always available and companies can lose autonomy if a venture capital firm wants to have a heavier hand in decisions. With the SBIR and STTR programs, funding is stable and predictable as it is an award, not a loan. Small businesses retain intellectual property rights. Additionally, the National Institute of Health (NIH), which oversees the programs, provides recognition, validation and visibility to early-stage companies that they might not otherwise have with either a loan from a bank or venture capital. Receiving an SBIR and STTR award can also help attract more funding because of the prestige associated with the programs. SBIR and STTR programs have supported the development of 99 drugs from 1996-2020. Of these drugs, 16% of all treatments made a “significant” advance over available medicines. Companies that receive SBIR and STTR awards are put on the map and can credibly say they were backed by the NIH. With the recent grants BioRestorative Therapies has received, the NIH has given the company a stamp of approval. To learn more about BioRestorative Therapies, visit its website. BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations ir@biorestorative.com Company Website https://www.biorestorative.com/

November 10, 2022 08:00 AM Eastern Standard Time

Article thumbnail News Release

Airly secures new $5.5M funding round to fight air pollution and save lives

Airly

Air pollution is the most-pressing environmental health crisis of our time with approximately nine in 10 people around the world breathing unclean air. Helping to spotlight this existential threat, cleantech startup Airly is today announcing a $5.5M series A funding round as it targets cleaning the air by understanding the exact sources based on sensor data and comprehensive actionable insights. The funding round was led by firstminute capital and Pi Labs with participation from existing investors including. Sir Richard Branson Family Office, AENU, Untitled and new investors including Slack co-founder Cal Henderson, Snowflake co-founder Marcin Zukowski as well as institutional investors Semapa Next and TO Ventures. With this funding round, Airly has raised $8.8M from investors since March 2021, as it now scales to realize the potential of its complete air quality monitoring platform and supporting local governments determined to fight for clean air with an end-to-end solution. The Airly platform provides solutions for air quality monitoring to local governments, companies and local communities in over 40 countries. They use sensors to observe data and now Airly will be able to provide a complete dashboard enabling users to go one step further. They will be able to monitor the data and obtain actionable insights that will translate into effective actions to improve air quality and understand their impact on health and well-being. The dashboard will offer multiple features including a report generator, insights, impact tracker and the city ranking. Wiktor Warchałowski, CEO and co-founder of Airly commented: “With the funding round we are going deeper with our users. Monitoring with our sensors has helped bring the issue to the surface and now with our dashboard offering actionable insights and nudges, we believe this will be the catalyst that helps move measures and policies into place to repair the air we breathe.” Recently, Airly launched the largest air quality monitoring network in a European city by installing 165 sensors in Warsaw. Similarly large networks have also been launched in the UK (Birmingham and the London boroughs of Lambeth, Haringey and soon Southwark) and Indonesia (Jakarta). Airly has also strategic partnerships with the likes of JCDecaux, NHS, NILU (Norwegian Institute for Air Research) and is a key partner in the European Union’s Horizon 2020 funded DivAirCity project. Airly impact studies have proven that cities with a dense network of air quality sensors are achieving faster reduction in air pollution. Since 2019, four cities from the C40 group (a global network of cities taking urgent action to confront the climate crisis) with dense monitoring networks (Jakarta, Lisbon, London and Warsaw) have improved their overall air quality by 16% (compared to 5% improvement made by cities without dense networks). “ Trailblazers in London are showing how real-time local air quality data is the catalyst for taking action to make our urban spaces healthier and more sustainable. I expect many cities and local authorities to follow their leadership, starting with more precise and local data. Airly is at the forefront of building this data infrastructure and our fight against air pollution, and we’re very proud to continue our support by co-leading their Series A” - says Brent Hoberman, co-founder and Executive Chairman of Founders Forum and firstminute capital. More than 10 million people die each year from air pollution. Exposure to air pollution increases the risk of stroke, dementia, heart disease, lung cancer and chronic respiratory diseases, with children particularly vulnerable. Last year, the World Health Organization tightened up on safe levels of air pollutants. Airly is the first platform worldwide to include the new index in its analytical tools and free-to-use community tools (incl. mobile app and web application). Stefania Ponzo, Partner at Pi Labs, commented: “ The ways in which towns and cities contribute to our health and wellbeing will shape how we live for years to come – and air quality plays a huge part in that. We believe Airly’s solution will become an essential tool in cities around the world, helping to improve liveability standards, reduce emissions, and ultimately, getting us closer to sustainability and wellness goals. We are excited at the prospect of partnering with a team that can truly go global with its impact.” About Airly Airly offers a comprehensive SaaS solution for air quality monitoring and control. It is possible by a proprietary low-cost distributed sensor network delivering hyper-local real-time air quality data. Airly provides governments, enterprises and communities decision-ready data on air quality. Airly enables organisations to monitor air quality, analyse trends and sources, develop targeted initiatives to combat pollution, and track improvements. Thanks to that, they’re supporting organisations in their journey to eliminate pollution, improve air quality and protect public health. Airly recently won a number of landmark public tenders such as London’s Borough Lambeth, Birmingham and one of Europe’s largest contracts with the City of Warsaw. Airly can build on a significant and ever growing customer base comprising over 600 local authorities. The company also cooperates with global brands such as JC Decaux, Bolt, E-on, Philips, Skanska and Veolia. For more information visit www.airly.org Contact Details Airly Marcin Gnat +48 507 416 727 m.gnat@airly.org Company Website https://airly.org/en/

November 10, 2022 07:00 AM Eastern Standard Time

Image
Article thumbnail News Release

UNOS Seeks New CEO to Be Voice for Diverse Needs of Donation and Transplant Community

United Network for Organ Sharing

United Network for Organ Sharing (UNOS) is conducting a national search for a permanent Chief Executive Officer. UNOS is the engine that powers the nation’s organ donation and transplant system under contract with the federal government. UNOS is seeking their next CEO, who will work collaboratively with the donation and transplant community, federal partners, Congress, and others to pursue projects and initiatives that build on ongoing successes while confronting the challenges facing the nation’s organ donation and transplant system. This includes leading the organization into a future, focusing on patient engagement, equity, innovation and driving increases in lifesaving transplants. The national search process is being conducted by a search committee at the direction of the UNOS Board of Directors and facilitated by Spencer Stuart, a global leader in executive searches with decades of experience. The Health Resources and Services Administration (HRSA) has also been involved in the process and will continue to provide feedback, as will members of the wider donation and transplant community. “We are committed to ensuring that all players in the system – patients, professionals and everyone else involved in our lifesaving mission – are represented in this process,” said Jerry McCauley, M.D., the President of the UNOS Board and the head of the candidate search committee. “We want to make sure that we’re inviting voices from different communities, experiences, and perspectives, and substantively incorporating that feedback into our process.” Maureen McBride, Ph.D. is currently serving as Interim CEO of UNOS and remains committed to focusing on continued system-wide advancement, including patient engagement and empowerment; advocating for holistic, evidence-based, patient-centered policy solutions at the federal level; and maximizing opportunities to better support research into equitable access to care. UNOS sought anonymous feedback from nearly 100 individuals to develop a representative candidate profile. These individuals are all actively engaged in the donation and transplant community, have experience in governance roles and have relevant knowledge of current issues and challenges facing the national system. These individuals also represented a broad spectrum of the donation and transplant community, covering an array of expertise, areas of involvement, backgrounds and perspectives and included patients, physicians, professionals, advocates and others. UNOS looks forward to completing the process and announcing the new CEO in the spring of 2023. “We have welcomed and will continue to welcome any and all ideas and feedback from members of the donation and transplant system,” McCauley said. “This inclusive process will result in a chosen candidate who is eager to lead a national organization of more than 400 employees, successfully compete for the next OPTN contract, convene the community, collaborate with partners at all levels and reach across barriers to drive continuous improvement.” About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

November 09, 2022 03:24 PM Eastern Standard Time

Article thumbnail Digital Asset Direct

Poolbeg Pharma makes virus "breakthrough" using AI drug discovery technology

Poolbeg Pharma PLC

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 09, 2022 08:51 AM Eastern Standard Time

Video
Article thumbnail News Release

As More Governments Continue to Legalize Cannabis, Suitable 420 Properties Continue to Grow

Benzinga

U.S. cannabis sales in 2021 topped $25 billion and are forecasted to reach $33 billion by the end of 2022. The industry’s rapid expansion has increased demand for buying and leasing cannabis properties. Finding suitable retail space is an issue many cannabis business owners face. 420 Property has made the search more convenient by listing cannabis real estate and businesses available to buy or rent. This property management company connects you with financial institutions to fund your business and professionals to help you with zoning and making the right investment decisions. Navigating Zoning Requirements for Cannabis Properties Zoning laws regulate land uses, enforcing certain restrictions on the property. Although your state’s law permits cannabis sales, a locality has specific zoning requirements. Each municipality enforces restrictions on properties, such as enabling cannabis businesses to operate only on specific streets, determining how and where the business can be advertised and prohibiting the business from being located within 1,000 feet of a school. The numerous limitations placed on cannabis business owners make it difficult for them to set up operations. Navigating local zoning requirements and finding the ideal site for your business is best achieved by working with a property management company. Getting into the Cannabis Industry the Right Way Setting up a cannabis business is a long-term investment that requires you to choose the best method of acquiring real estate. That helps you budget and increases your chances of success. Cannabis Real Estate for Sale Buying cannabis real estate requires you to find a green-zoned property. The ideal way to finance it is with cash. Some banks are allowed to issue loans to cannabis businesses, but they’re accompanied by high fees and interest rates. Investors can choose from several premium cannabis real estate listings in California, New Jersey, Illinois, Oregon, Washington and Michigan. If those listings aren’t suitable, more are available on 420 Property. Cannabis Real Estate for Lease One of the benefits of leasing a property for your cannabis business is that you’re not concerned about the market tanking and decreasing the value of your property. Leasing retail space also requires you to have less upfront capital than buying real estate. Exiting an unsuccessful venture is more viable if you rent rather than own the property. But a major challenge entrepreneurs in the cannabis industry face is high rent. Fortunately, it’s possible to find affordable cannabis retail space to rent. You can visit 420 Property ’s website for a larger selection of real estate to lease. Cannabis Businesses for Sale Setting up a cannabis company from scratch and acquiring all the licenses, equipment and establishing a client base can be an arduous and lengthy process. You can circumvent those challenges by buying an existing cannabis business. Choose a cannabis business for sale or check out 420 Property to connect with a broker who will help you find a great offer. Cannabis Investment Opportunities Instead of setting up a business and being involved in the operations, you can profit from the cannabis industry as an investor and earn passive income. Select the best cannabis investment opportunity and let your money work for you. 420 Property lists numerous investment options for you to explore. Cannabis Real Estate Has Massive Growth Potential Considering that some experts predict the cannabis industry will reach $70 billion in annual sales by 2030, demand for cannabis real estate is rising. You require the assistance of a property management company that will provide guidance about zoning requirements and assist in finding real estate that suits your needs. You can find cannabis listings, financing, insurance, and cannabis real estate brokers on 420 property Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 08, 2022 04:25 PM Eastern Standard Time

Article thumbnail Digital Asset Direct

Unicycive’s Doug Jermasek, EVP-Corporate Development Discusses the Importance of Medication Compliance and the Issues with Pill Burden

Unicycive Therapeautics, Inc.

Contact Details Anne Marie Fields - Stern Investor Relations +1 212-362-1200 annemarie.fields@sternir.com Company Website https://unicycive.com/

November 08, 2022 09:00 AM Eastern Standard Time

Video
Article thumbnail News Release

First-of-its-kind global study finds the pandemic widely increased public scrutiny, but not understanding, of scientific research

Elsevier

New ‘Confidence in research: researchers in the spotlight’ report by Economist Impact, supported by Elsevier, reveals researchers’ outlook on global research landscape and concerns around misinformation, online abuse and widening of inequalities. Researchers are concerned about the challenges of greater public interest in scientific research, but the majority believe it has never been more important for them to engage in debate and help counter false information. The landmark ‘Confidence in research: researchers in the spotlight’ report published today finds that nearly two thirds of scientific researchers surveyed (63%) feel the pandemic has increased public attention on research. But only 38% think that better public understanding of research will be a legacy of the pandemic. (i) Conducted by Economist Impact and supported by Elsevier, a global leader in scientific publishing and information analytics, the report combines the findings from a global survey of over 3,000 scientists, scholars and researchers on how the pandemic has affected the practice of undertaking and communicating research in the face of increased public scrutiny. The full report includes recommendations for potential solutions from a Global Expert Panel of researchers, academic leaders, science organisations and policy makers. Being published in a peer-reviewed journal is the most important marker of reliability according to 74% of researchers surveyed. The study also reveals that more than half of researchers (52%) feel the pandemic increased the importance of publishing research early, prior to peer review, and many – particularly women, early career researchers and those in Global South countries – feel the pandemic has widened inequalities in, and access to, funding in their fields. More than half of respondents expressed concern about the challenges of over-simplification(52%) and the politicisation of research (56%) because of increased public attention and social media focus on research and the research process. As a result, many say they now lack confidence in their ability to communicate their findings to the public in this new environment. Fewer than one in five researchers (18%) participating in the study feel highly confident in communicating their findings on social media. This is against a background of nearly a third (32%) of respondents having experienced, or knowing a close colleague who has experienced abuse after posting research online. Half of all researchers surveyed (51%) say they feel a responsibility to engage in debate online and over two thirds (69%) believe the pandemic has increased the importance of separating quality research from misinformation. In fact, misinformation has become such a concern globally in recent years that nearly a quarter of academics (23%) now see publicly countering it as one of their primary roles in society, compared to just 16% who said this was the case before the pandemic. Alongside supporting the landmark survey by Economist Impact, Elsevier partnered with leading science and research organisations (ii) to bring together world-renowned experts, academic leaders and early career researchers to explore the impact of the pandemic on researchers and to identify potential areas of action to help the research community and enhance confidence in research. Economist Impact has combined the findings from the global survey with the insights from the extensive stakeholder dialogue to develop recommendations, which are set out in the ‘Confidence in research: researchers in the spotlight’ report published today. These include: Providing formal communications training to give researchers the tools and guidance to communicate ethically, effectively and with confidence, and incentivising strong communication skills as part of career development; Providing support for researchers in the face of online abuse by drafting clear codes of conduct and guidance on how to manage online interaction; Embedding the right incentive and reward structures to ensure that researchers’ contribution to furthering confidence in science receives appropriate recognition, in particular their role in teaching, public engagement and participation in the peer review process; Promoting collaboration and impact by providing financial incentives for researchers to collaborate in larger teams and facilitate quality trials and studies over quantity; Prioritising equity and diversity by directing research funding to countries and research communities that need it most; Adopting more digestible summaries and user-friendly formats to make it easier for policymakers, journalists or the general public to better understand and identify quality research; Prioritising consistency in R&D spending to ensure that researchers can properly plan their research, staffing and infrastructure needs. Laura Hassink, Managing Director of Scientific, Technical and Medical Journals at Elsevier, said: “The pandemic showed just how important quality research is for addressing global challenges and accelerating progress for society. Science is advancing at an extraordinary pace but that has brought new pressures on researchers such as tackling damaging misinformation, handling public scrutiny, and communicating their work with confidence. The Economist Impact report can be a helpful stimulus as all stakeholders in research come together to turn recommendations into action. At Elsevier, we are committed to supporting the research community to tackle these challenges and thank our expert partners and the thousands of academic leaders, scientists and researchers who lent their invaluable perspectives to this important collaboration.” Tracey Brown, Director, Sense about Science, and chair of a Global Expert Panel that discussed the findings said: “People who use research evidence need to know what weight they can put on it, and the pandemic exploded the numbers of people who use research evidence by millions. Researchers had to bring decision makers, the public and reporters in on all those questions about how reliable a study is, and how convincing its findings are. And they did this – they did it incredibly well the world over, with innovation and determination, but at some price. This research is a step to figuring out how to take the benefits forward, and address the challenges that make it unnecessarily difficult to talk about what we know and how.” Jonathan Birdwell, Regional Head of Policy Research & Insights for EMEA, Economist Impact said: “The pandemic demonstrated the research community’s ability to come together and solve global problems. It increased public attention on that community like never before, presenting opportunities for open science and policy influence, but also challenges around higher volume, speed and demand for simple stories. But do researchers have confidence to embrace a more public-facing role? And are their support structures and incentives fit-for-purpose amidst this new landscape? Our research finds that many researchers want to solve societal problems, influence policy and boost public understanding of research. But to do so confidently, they need more time to devote to communication, support in the face of online abuse and recognition of their public-facing contributions.” Notes to editors Statistical references / methodology (i) Economist Impact’s research was conducted with 3,144 active researchers globally between May and August 2022, spanning 100 countries and dozens of fields of expertise. (N.B. active is defined as having published an article within the last three years). This quantitative research was informed by a literature review and supplemented with qualitative in-depth interviews with a range of independent research experts, plus a Global Advisory Board. (ii) In addition to the quantitative survey and expert interviews, insights were also gathered from six regional roundtables led by Elsevier’s regional convening partners: Chinese Association for Science of Science and Science & Technology Policy (China) Japanese Association for the of Advancement Science (Japan) Koninklijke Hollandsche Maatschappij der Wetenschappen, (Netherlands) Körber Stiftung (Germany) Research!America (United States) Sense about Science (UK) Combined, these roundtables featured the perspectives of around 200 researchers covering approximately 14 countries. (iii) The survey findings, insights from the qualitative in-depth interviews and the regional roundtables were discussed by a Global Expert Panel, convened by Elsevier, which contributed recommendations for action and further exploration. These were collated by the Economist Impact and set out in the full report. More information on the methodology of the study and a full list of the experts consulted can be viewed via the report. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,700+ journals, including The Lancet and Cell; our 43,000+ eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com About Economist Impact Economist Impact combines the rigour of a think-tank with the creativity of a media brand to engage a globally influential audience. We believe that evidence-based insights can open debate, broaden perspectives and catalyse progress across three core areas of expertise and leadership including sustainability, new globalisation and health. The services offered by Economist Impact previously existed within The Economist Group as separate entities, including EIU Thought Leadership, EIU Public Policy, Economist Events and SignalNoise. Our track record spans 75 years across 205 countries. Along with creative storytelling, events expertise, design-thinking solutions and market-leading media products, we produce framework design, benchmarking, economic and social impact analysis, forecasting and scenario modelling, making Economist Impact's offering unique in the marketplace. Visit www.economistimpact.com for more information. About Sense about Science Sense about Science is an independent non-profit that promotes the public interest in sound science and evidence. It produced the first public guide to peer review, ‘I Don’t Know What to Believe’ over a decade ago, and has since produced the first international guide to data science, co-created with user groups around the world. With its AllTrials campaign, with patients, doctors and researchers, it has achieved major changes in international regulation and compliance on the publication of clinical trial results. Sense about Science chaired the Global Expert Panel, to develop plans for improving scientific practices and helping researchers and the public to navigate research outputs. It represents UK-based stakeholders as the local Regional Convening Partner, to draw people into a discussion of what actions and interventions researchers, scholarly publishers, universities, funders and others can make to improve confidence in research in the UK. Media contacts Andrea White Elsevier Global Communications +44 7876 397206 a.white@elsevier.com Dan DiPietro-James Global Media Relations Director +1 773-251-8744 dan.james@elsevier.com Esra Erkal EVP Global Communications +44 7500 992819 e.erkal@elsevier.com Claudine Cornelis Economist Impact claudinecornelis@economist.com Harry Saunders Teneo +44 7901 313198 Harry.Saunders@teneo.com Contact Details Dan DiPietro-James dan.james@elsevier.com Company Website https://www.elsevier.com/

November 07, 2022 07:01 PM Eastern Standard Time

Article thumbnail News Release

What Does Sunshine Biopharma’s Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market?

Sunshine Biopharma Inc.

The generic drug market has been growing since 1984 when the Hatch-Waxman Act encouraged manufacturing generics and developed a framework to regulate them. Apart from name difference, generic drugs work the same as an already marketed brand-name drug in dosage form, safety, strength, administration, quality, performance characteristics and intended use. Generic drug manufacturers can apply to the U.S. Food and Drug Administration (FDA) for permission to produce drugs when a patent expires. Generic drugs typically cost 80% to 85% less than branded drugs. If you look at your medications, chances are you will find one or more generic drugs such as ibuprofen, famotidine, metformin, metoprolol and amphetamine salt combo. Growing Global Generic Drugs Market The popularity, need for and use of these drugs are fueling the growth of the global generic drug market, which is expected to grow at a compound annual growth rate (CAGR) of 7.24% from 2022 to 2027. The market is expected to be worth $311.8 billion this year and $442.3 billion by 2027. Companies like Sol-Gel Technologies Ltd. (NASDAQ: SLGL), Viatris Inc. (NASDAQ: VTRS) and Sunshine Biopharma Inc. (NASDAQ: SBFM) are researching, running trials and releasing products to meet demand. Strategic Acquisition By Sunshine Biopharma As the market continues to grow, strategic acquisitions like Sunshine Biopharma ’s recent purchase of Nora Pharma Inc. could help shape the future of the generic drugs market. Nora Pharma is now a wholly owned subsidiary of Sunshine after the acquisition of its outstanding shares. The purchase price of approximately $21.9 million was paid by cash, Sunshine Biopharma common stock, and an earn-out amount. Nora Pharma is one of North America’s fastest-growing generic pharmaceutical companies, according to the news release issued Oct. 20. This acquisition allows Sunshine Biopharma to expand its operations into generic prescription drugs and biosimilars. “The strategic acquisition of Nora Pharma significantly expands our revenue stream and is expected to generate multiyear top-line and bottom-line growth going forward,” Sunshine Biopharma CEO Steve Slilaty said. “This acquisition gives Sunshine a solid position in the generic prescription drugs industry and brings us closer to our objective of becoming a fully integrated pharma company.” Nora Pharma Founder and President said Sunshine will provide additional expertise that will help Nora with its accelerated growth plan to provide high-quality, affordable medicines to the Canadian market. Nora Pharma has 36 employees working at its 15,000-square-foot Health Canada-certified facility and offers over 50 pharmaceutical products, including generic prescription drugs, over-the-counter products and biosimilars. Nora Pharma and its service arm, which commercializes under the name Lea Solutions, will continue to operate without changes. “Nora Pharma will operate as a subsidiary of Sunshine Biopharma, with Mr. Chamoun as president,” Slilaty said. “We are happy to have the Nora employees join the Sunshine Biopharma family.” About Sunshine Biopharma Sunshine Biopharma (NASDAQ: SBFM) is a fully integrated pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. In addition to working with the University of Arizona to develop a treatment for COVID-19, the company also develops Adva-27a, a unique anti-cancer compound. Sunshine Biopharma reports that tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying multidrug-resistant cancer cells, including pancreatic, small-cell lung, breast and uterine sarcoma cancer cells. Clinical trials for pancreatic cancer indication will be conducted at McGill University’s Jewish General Hospital in Montreal, Canada, the company said. Sunshine Biopharma is also engaged in developing a novel anti-cancer mRNA called K1.1. The company says the data collected to date has shown that K1.1 mRNA is capable of destroying cancer cells in vitro, including multidrug-resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3) and pancreatic cancer cells (SUIT-2). Studies using nontransformed (normal) human cells (HMEC) have shown that K1.1 mRNA had little or no cytotoxic effects. K1.1 mRNA is readily adaptable for delivery to patients using the proven mRNA vaccine technology. Learn more about the company here. In addition to working with the University of Arizona on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is also engaged in the development of a novel anticancer mRNA called K1.1. The data collected to date have shown that K1.1 mRNA is capable of destroying cancer cells in vitro including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Studies using non-transformed (normal) human cells (HMEC) have shown that K1.1 mRNA had little or no cytotoxic effects. K1.1 mRNA is readily adaptable for delivery into patients using the proven mRNA vaccine technology. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Christine Petraglia - TraDigital IR +1 917-633-8980 investors@sunshinebiopharma.com Company Website https://sunshinebiopharma.com/

November 07, 2022 09:28 AM Eastern Standard Time

Video
1 ... 193194195196197 ... 308